Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.86), $1.24 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $242.7 million versus the consensus estimate of $270.94 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.